Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 11/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31353318 | 0.92 | ESR2 (0.40) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL342968 | 0.91 | LPL (0.46) | ESR2LPLLIPGOPRM1CA1 | |
| SCHEMBL238507 | 0.88 | LPL (0.44) | ESR2LPLLIPGOPRM1CA1 | |
| SCHEMBL12077932 | 0.88 | LPL (0.44) | ESR2LPLLIPGOPRM1CA1 | |
| SCHEMBL30900711 | 0.84 | ESR2 (0.41) | ESR2LPLLIPGOPRM1CA1 | |
| SCHEMBL234668 | 0.80 | ESR2 (0.40) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL13778138 | 0.80 | OPRM1 (0.43) | ESR2LPLLIPGOPRM1 | |
| SCHEMBL23571317 | 0.79 | LPL (0.40) | ESR2LPLLIPGOPRM1 | |
| SCHEMBL15774984 | 0.77 | LPL (0.45) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL17129428 | 0.77 | DGAT1 (0.47) | ESR2LPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950676-B1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND APPLICATION THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12595267-B2 | Preparation method for amide compound and application thereof in field of medicine | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220098178-A1 | Preparation Method for Amide Compound and Application Thereof in Field of Medicine | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3950676-A1 | PREPARATION METHOD FOR AMIDE COMPOUND AND APPLICATION THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950676-A1 | PREPARATION METHOD FOR AMIDE COMPOUND AND APPLICATION THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-02-09 | — | — | EP | disclosed |
| CN-113631541-A | Preparation method of amide compound and application of amide compound in field of medicine | 上海华汇拓医药科技有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2020192650-A1 | PREPARATION METHOD FOR AMIDE COMPOUND AND APPLICATION THEREOF IN FIELD OF MEDICINE | 上海华汇拓医药科技有限公司 | 2020-10-01 | — | — | WO | disclosed |
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| EP-2681206-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2012121992-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012121992-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | ESR2 1033/4885LPL 3628/4885LIPG 1609/4885 |
| US-12595267-B2 | Preparation method for amide compound and application thereof in field of medicine | EZH2, BMI1, EHMT1 | ESR2 246/4885LPL 3266/4885LIPG 4054/4885 |
| US-20220098178-A1 | Preparation Method for Amide Compound and Application Thereof in Field of Medicine | EZH2, EZH1, IKZF2 | ESR2 482/4885LPL 3479/4885LIPG 2952/4885 |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | ESR2 1033/4885LPL 3628/4885LIPG 1609/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | ESR2 805/4885LPL 2363/4885LIPG 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.